Display again
EUCTR2017-001225-41

A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Crohn's Disease who Completed the Studies M14-431 or M14-433

Data source: WHO (Imported from 02.08.2020)
Changed: 02.08.2020
Disease category:

Health conditions (Data source: WHO)

Crohn's Disease (CD)
MedDRA version: 20.0Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]

Interventions (Data source: WHO)


Product Name: Upadacitinib
Product Code: ABT-494
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: Upadacitinib
CAS Number: 1310726-60-3
Other descriptive name: ABT-494
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 30-
Pharmaceutical form of the placebo: Film-coated tablet
Route of administration of the placebo: Oral use

Product Name: Upadacitinib
Product Code: ABT-494
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: Upadacitinib
CAS Number: 1310726-60-3
Other descriptive name: ABT-494
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 15-
Pharmaceutical form of the placebo: Film-coated tablet
Route of administration of the placebo: Oral use

Inclusion/Exclusion Criteria (Data source: WHO)

Inclusion criteria:
For Substudy 1:
- Subject who receive double-blind treatment in Study M14- 431 or Study M14-433 and achieve clinical response.
- Subject completes Week 12 study procedures in study M14-431 or study M14-433. The final endoscopy for studies M14-431 or M14-433 may be missing, if the endoscopy cannot be performed during the coronavirus SARS-CoV-2 pandemic.
For Substudy 2:
- Subject completes Substudy 1 of Study M14-430. The week 52 endoscopy may be missing, if the endoscopy cannot be performed during the coronavirus SARS-CoV-2 pandemic.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 710
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 37

Exclusion criteria:
For Sub-studies 1 and 2:
- Subject is considered by the investigator, for any reason, to be an unsuitable candidate for the study.
- Subject who has a known hypersensitivity to upadacitinib or its excipients, or had an adverse event during Study M14-431, M14-433,or Substudy 1 of Study M14-430 that in the investigator's judgment makes the subject unsuitable for this study.
- Subject with any active or chronic recurring infections based on the investigator's assessment that makes the subject an unsuitable candidate for the study. Subjects with serious infections undergoing treatment may be enrolled BUT NOT dosed until the infection treatment has been completed and the infection is resolved, based on the investigator's assessment.
- Subject with high grade colonic dysplasia or malignancy diagnosed at the endoscopy performed at the final visit of Study M14-431, M14-433,or Substudy 1 of Study M14-430 (Week 52).

Further information on the trial in WHO primary registry

https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-001225-41

Further information on the trial from WHO database (ICTRP)

http://apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2017-001225-41-HU

Further information on trial

Date trial registered

07.03.2018

Incorporation of the first participant

18.05.2018

Recruitment status

Authorised-recruitment may be ongoing or finished

Academic title (Data source: WHO)

A Multicenter, Randomized, Double-Blind, Placebo- Controlled Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Crohn's Disease who Completed the Studies M14-431 or M14-433

Type of trial (Data source: WHO)

Interventional clinical trial of medicinal product

Design of the trial (Data source: WHO)

Controlled: yes
Randomised: yes
Open: no
Single blind: no
Double blind: yes
Parallel group: no
Cross over: no
Other: yes
Other trial design description: Substudy 1 Randomized, double-blind. Substudy 2 Both open-label and double-blind
If controlled, specify comparator, Other Medicinial Product: no
Placebo: yes
Other: no
Number of treatment arms in the trial: 3

Phase (Data source: WHO)

Human pharmacology (Phase I): noTherapeutic exploratory (Phase II): noTherapeutic confirmatory - (Phase III): yesTherapeutic use (Phase IV): no

Primary end point (Data source: WHO)

Main Objective: Substudy 1 (randomized, double-blind, placebo-controlled maintenance): To evaluate the efficacy and safety of two doses of upadacitinib versus placebo as maintenance therapy in subjects with moderately to severely active Crohn's disease (CD) who responded to upadacitinib induction treatment in Studies M14-431 or M14-433.
Substudy 2 (long-term extension [LTE]): To evaluate safety and efficacy of long-term administration of upadacitinib in subjects with moderately to severely active CD who participated in the Phase 3 upadacitinib induction and maintenance studies.;Secondary Objective: To evaluate improvements in several efficacy parameters, including steroid discontinuation, laboratory parameters and quality of life questionnaires.;Primary end point(s): Substudy 1, Cohort 1 (Upadacitinib vs Placebo)
Co-Primary Endpoints:
? Proportion of subjects with clinical remission per PROs at Week 52, AND
? Proportion of subjects with endoscopic response at Week 52

Substudy 2
Primary Endpoint: Incidence of AEs over time
;Timepoint(s) of evaluation of this end point: Week 52

Secundary end point (Data source: WHO)

Secondary end point(s): Substudy 1
1. Proportion of subjects with clinical remission per CDAI (CDAI < 150) at Week 52
2. Proportion of subjects with clinical remission at Week 0 and Week 52
3. Proportion of subjects with endoscopic remission at Week 52
4. Change in Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) at Week 52
5. Proportion of subjects achieving CR-100 at Week 52
6. Change from Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) at Week 52
7. Proportion of subjects with clinical remission and endoscopic remission at Week 52
8. Proportion of subjects who discontinue corticosteroid use for CD at 90 days and achieve clinical remission per PROs at Week 52 in subjects taking corticosteroids for CD at Baseline of induction
9. Proportion of subjects with CD-related hospitalizations during the 52-Week double-blind maintenance period.
10. Proportion of subjects with resolution of extra-intestinal manifestation (EIM) at Week 52, in subjects with EIMs at Baseline.

Substudy 2
Proportion of subjects
? with clinical remission per PROs over time
? with enhanced clinical response per PROs over time
? with clinical response per PROs over time
? with clinical remission per CDAI (CDAI<150) over time
? with CR-100 over time
? with endoscopic remission at Week 0, and every 48 weeks thereafter
? with endoscopic response at Week 0, and every 48 weeks thereafter
? who discontinue corticosteroid use and achieve clinical remission per PROs over time among subjects taking steroids at Baseline (of induction)

Time loss of
? enhanced clinical response
? clinical remission
;Timepoint(s) of evaluation of this end point: Substudy 1
1. week 52
2. week 52
3. week 52
4. week 52
5. week 52
6. week 52
7. week 52
8. week 52
9. week 52
10. week 52

Substudy 2
Over study duration

Contact information (Data source: WHO)

AbbVie Inc.

Trial results (Data source: WHO)

Results summary

A Multicenter, Randomized, Double-Blind, Placebo- Controlled Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects with Crohn's Disease who Completed the Studies M14-431 or M14-433

Link to the results in the primary register

no information available yet

Information on the availability of individual participant data

no information available yet

Trial sites

Countries (Data source: WHO)

Argentina, Australia, Austria, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czech Republic, Denmark, Egypt, Germany, Hong Kong, Hungary, Ireland, Israel, Japan, Korea, Latvia, Lithuania, Malaysia, Mexico, Netherlands, Portugal, Puerto Rico, Republic of, Russian Federation, Serbia, Singapore, Slovakia, Slovenia, South Africa, Spain, Sweden, Switzerland, Taiwan, Turkey, Ukraine, United Kingdom, United States

Contact for further information on the trial

Contact for general information (Data source: WHO)

EU Clinical Trials Helpdesk
AbbVie House, Vanwall Business Park, Vanwall Road
AbbVie Ltd
441628561090
eu-clinical-trials@abbvie.com

Contact for scientific information (Data source: WHO)

EU Clinical Trials Helpdesk
AbbVie House, Vanwall Business Park, Vanwall Road
AbbVie Ltd
441628561090
eu-clinical-trials@abbvie.com

Principal Sponsor/Investigator

Principal sponsor (Data source: WHO)

AbbVie Deutschland GmbH & Co. KG

Further trial identification numbers

Secondary ID (Data source: WHO)

M14-430
2017-001225-41-SK